Amylin Pharmaceuticals amylin.com


Public lists: Pharma Startups (4732)

Amylin Pharmaceuticals is engaged in the discovery and development of potential drug candidates for the treatment of metabolic disorders. The Company is developing SYMLIN for the treatment of people with diabetes who use insulin.

Amylin Pharmaceuticals is engaged in the discovery and development of potential drug candidates for the treatment of metabolic disorders. The Company is developing SYMLIN for the treatment of people with diabetes who use insulin.

Company (Acquired)

Phone: 858-552-2200

Fax: (858) 552-2212

9360 Towne Centre Drive

San Diego, 92121
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Amylin Pharmaceuticals $56M Aug 9, 2012
Intarcia Therapeutics $1513.7M Apr 3, 2017
Nurel Therapeutics $0M Nov 22, 2005
See all 19 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Amylin Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 19 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Methods for treating diabetes and reducing body weight May 31, 2016 Feb 06, 2018 Patent
Engineered polypeptides having enhanced duration of action Mar 28, 2013 Mar 14, 2017 Patent
Hybrid polypeptides with selectable properties Mar 03, 2014 Sep 27, 2016 Patent
Engineered polypeptides having enhanced duration of action with reduced immunogenicity Jul 03, 2012 Jul 05, 2016 Patent
C-terminal amidation of polypeptides Sep 08, 2011 Feb 02, 2016 Patent
See all 120 patents